{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:24:09Z","timestamp":1792265049571,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["634413"],"award-info":[{"award-number":["634413"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["777377"],"award-info":[{"award-number":["777377"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012295","name":"NIHR Newcastle Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012295","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jhepr.2022.100477","type":"journal-article","created":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T17:53:13Z","timestamp":1648317193000},"page":"100477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6682-6030","authenticated-orcid":false,"given":"Aidan J.","family":"McGlinchey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4426-6930","authenticated-orcid":false,"given":"Olivier","family":"Govaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3677-3294","authenticated-orcid":false,"given":"Michael","family":"Allison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Bousier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0822-9673","authenticated-orcid":false,"given":"Salvatore","family":"Petta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"de Oliviera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0502-4381","authenticated-orcid":false,"given":"Elisabetta","family":"Bugianesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-4703","authenticated-orcid":false,"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7321-0629","authenticated-orcid":false,"given":"Ann K.","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuulia","family":"Hy\u00f6tyl\u00e4inen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin M.","family":"Anstee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2856-9165","authenticated-orcid":false,"given":"Matej","family":"Ore\u0161i\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2022.100477_bib1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100477_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.jhepr.2022.100477_bib3","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100477_bib4","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2022.100477_bib5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2019.04.019","article-title":"Anstee QM, participants of the AASLD\/EASL Workshop. Report on the AASLD\/EASL joint workshop on clinical trial endpoints in NAFLD","volume":"71","author":"Rinella","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100477_bib6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","article-title":"Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort","volume":"73","author":"Anstee","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100477_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba4448","article-title":"Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis","volume":"12","author":"Govaere","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2022.100477_bib8","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41575-021-00502-9","article-title":"Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests","volume":"18","author":"Masoodi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100477_bib9","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jhep.2016.01.002","article-title":"Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease","volume":"64","author":"Luukkonen","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100477_bib10","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1007\/s00125-013-2981-2","article-title":"Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids","volume":"56","author":"Ore\u0161i\u010d","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhepr.2022.100477_bib11","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1194\/jlr.P056002","article-title":"Biomarkers of NAFLD progression: a lipidomics approach to an epidemic","volume":"56","author":"Gorden","year":"2015","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhepr.2022.100477_bib12","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1021\/pr201223p","article-title":"Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression","volume":"11","author":"Barr","year":"2012","journal-title":"J\u00a0Proteome Res"},{"key":"10.1016\/j.jhepr.2022.100477_bib13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/hep.21763","article-title":"A\u00a0lipidomic analysis of nonalcoholic fatty liver disease","volume":"46","author":"Puri","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100477_bib14","doi-asserted-by":"crossref","first-page":"100104","DOI":"10.1016\/j.jlr.2021.100104","article-title":"Nonalcoholic fatty liver disease stratification by liver lipidomics","volume":"62","author":"Vvedenskaya","year":"2021","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhepr.2022.100477_bib15","doi-asserted-by":"crossref","first-page":"106175","DOI":"10.1016\/j.cct.2020.106175","article-title":"The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease","volume":"98","author":"Hardy","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jhepr.2022.100477_bib16","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100477_bib17","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"Bedossa","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100477_bib18","doi-asserted-by":"crossref","first-page":"105935","DOI":"10.1016\/j.envint.2020.105935","article-title":"Prenatal exposure to perfluoroalkyl substances modulates neonatal serum phospholipids, increasing risk of type 1 diabetes","volume":"143","author":"McGlinchey","year":"2020","journal-title":"Environ Int"},{"key":"10.1016\/j.jhepr.2022.100477_bib19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/1471-2105-11-395","article-title":"MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data","volume":"11","author":"Pluskal","year":"2010","journal-title":"Bmc Bioinformatics"},{"key":"10.1016\/j.jhepr.2022.100477_bib20","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1021\/ac103308x","article-title":"Data analysis tool for comprehensive two-dimensional gas chromatography\/time-of-flight mass spectrometry","volume":"83","author":"Castillo","year":"2011","journal-title":"Anal Chem"},{"key":"10.1016\/j.jhepr.2022.100477_bib21","series-title":"R: A Language and Environment for Statistical Computing","year":"2017"},{"key":"10.1016\/j.jhepr.2022.100477_bib22","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2022.100477_bib23","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.2337\/dc18-0071","article-title":"Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars","volume":"41","author":"Luukkonen","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhepr.2022.100477_bib24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100477_bib25","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1053\/j.gastro.2010.06.064","article-title":"Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease","volume":"139","author":"Westerbacka","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2022.100477_bib26","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s00125-009-1282-2","article-title":"Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations","volume":"52","author":"Kotronen","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhepr.2022.100477_bib27","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1172\/JCI44442","article-title":"Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans","volume":"121","author":"Rhee","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhepr.2022.100477_bib28","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1111\/liv.14943","article-title":"Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)","volume":"41","author":"Burra","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2022.100477_bib29","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.31312","article-title":"Hepatic molecular signatures highlight the sexual dimorphism of nonalcoholic steatohepatitis (NASH)","volume":"73","author":"Vandel","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100477_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010883","article-title":"alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population","volume":"5","author":"Gall","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2022.100477_bib31","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2337\/db12-0707","article-title":"Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance","volume":"62","author":"Ferrannini","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.jhepr.2022.100477_bib32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s13238-017-0423-5","article-title":"Structural and functional roles of ether lipids","volume":"9","author":"Dean","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.jhepr.2022.100477_bib33","article-title":"Ether lipids, sphingolipids and toxic 1-deoxyceramides as hallmarks for lean and obese type 2 diabetic patients","volume":"232","author":"Hannich","year":"2020","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1016\/j.jhepr.2022.100477_bib34","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.2337\/dc18-0840","article-title":"Plasma lipidomic profiling and risk of type 2 diabetes in the PREDIMED trial","volume":"41","author":"Razquin","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhepr.2022.100477_bib35","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2337\/db12-0495","article-title":"Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach","volume":"62","author":"Floegel","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.jhepr.2022.100477_bib36","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/msb.2012.43","article-title":"Novel biomarkers for pre-diabetes identified by metabolomics","volume":"8","author":"Wang-Sattler","year":"2012","journal-title":"Mol Syst Biol"},{"key":"10.1016\/j.jhepr.2022.100477_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2017.08.014","article-title":"Lipidome as a predictive tool in progression to type 2 diabetes in Finnish men","volume":"78","author":"Suvitaival","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.jhepr.2022.100477_bib38","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/db17-1449","article-title":"Circulating sphingolipids, insulin, HOMA-IR, and HOMA-B: the strong heart family study","volume":"67","author":"Lemaitre","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.jhepr.2022.100477_bib39","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1194\/jlr.S087163","article-title":"MS-based lipidomics of human blood plasma: a community-initiated position paper to develop accepted guidelines","volume":"59","author":"Burla","year":"2018","journal-title":"J\u00a0Lipid Res"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555922000490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555922000490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T20:09:13Z","timestamp":1762632553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555922000490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2589555922000490"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2022.100477","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2022.100477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100477"}}